Reported fourth quarter 2023 revenue from continuing operations1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross.
GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2023 Earnings Call Transcript February 20, 2024 GeneDx Holdings Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to the GeneDx Fourth Quarter 2023 Earnings Conference Call. At […]
By Zaeem Shoaib GeneDx Holdings shares jumped Wednesday after the company reported better-than-expected results for the fourth quarter and reiterated a path.